- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.04. | Health Check: Investors say "not baa-d" as Aroa smashes earnings expectations out of the paddock | 3 | Stockhead | ||
| 29.04. | AROA BIOSURGERY LIMITED: ARX FY26 Preliminary Results | - | ASX | ||
| 10.04. | AROA BIOSURGERY LIMITED: Application for quotation of securities - ARX | - | ASX | ||
| 09.04. | AROA BIOSURGERY LIMITED: Notification of cessation of securities - ARX | - | ASX | ||
| 30.03. | Aroa Biosurgery's Symphony Shows Positive Preliminary Results For Diabetic Foot Ulcers | 2 | RTTNews | ||
| 30.03. | AROA Biosurgery Completes Randomised Controlled Trial for Symphony; Preliminary Read-Out indicates Primary Endpoint Met | 312 | PR Newswire | AUCKLAND, New Zealand, March 29, 2026 /PRNewswire/ -- Aroa Biosurgery Limited today announced completion of its randomised controlled trial (RCT) evaluating Symphony... ► Artikel lesen | |
| AROA BIOSURGERY Aktie jetzt für 0€ handeln | |||||
| 29.03. | AROA BIOSURGERY LIMITED: Symphony Randomised Control Trial Complete | - | ASX | ||
| 24.03. | AROA BIOSURGERY LIMITED: Release of Shares from Voluntary Escrow | 1 | ASX | ||
| 10.03. | Vital Signs Podcast: Inside Aroa's MASTRR clinical registry | 1 | Stockhead | ||
| 03.02. | AROA BIOSURGERY LIMITED: Application for quotation of securities - ARX | - | ASX | ||
| 03.02. | AROA BIOSURGERY LIMITED: Eligible NZ Employees Issued with ARX Shares | - | ASX | ||
| 02.02. | AROA BIOSURGERY LIMITED: AROA Business Update Presentation | - | ASX | ||
| 02.02. | AROA BIOSURGERY LIMITED: AROA Business Update | - | ASX | ||
| 27.01. | AROA BIOSURGERY LIMITED: Notification of Investor Webinar | - | ASX | ||
| 22.01. | AROA BIOSURGERY LIMITED: Study Demonstrates Effectiveness & Economic Value of Myriad | 1 | ASX | ||
| 09.01. | AROA BIOSURGERY LIMITED: Notification of cessation of securities - ARX | 1 | ASX | ||
| 18.12.25 | AROA BIOSURGERY LIMITED: Symphony Outpatient Reimbursement Update | - | ASX | ||
| 17.12.25 | Multi-channel sales strategy drives growth for tissue repair biotech Aroa | 20 | Stockhead | ||
| 25.11.25 | Aroa Biosurgery Reports NZ$44.9m in Product Revenue for First Six Months of FY26 | 1 | smallcaps.com.au | ||
| 25.11.25 | Health Check: It's quarterly report 'Liberation Day' for Aroa after a bumper first half result | 1 | Stockhead |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,70 | -0,13 % | Aktien im Fokus - LPKF Laser: Party bald vorbei? - BioNTech, BVB, Elmos, Rheinmetall und Verbio | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| EVOTEC | 5,080 | -2,31 % | Evotec im Umbau: Verlust steigt, Strategie-Prüfung läuft | Das Biotech-Unternehmen Evotec erzielte im ersten Quartal 2026 einen Konzernumsatz von 156,6 Millionen Euro, nach knapp 200 Millionen Euro im Vorjahreszeitraum. Der Rückgang erklärt sich nach ANgaben... ► Artikel lesen | |
| MODERNA | 45,405 | +0,09 % | Moderna: Hantavirus-Schlagzeilen treiben Impfstoff-Aktie an | Das Hantavirus ist auf einem kleinen Kreuzfahrtschiff im Atlantik ausgebrochen. Die Weltgesundheitsorganisation (WHO) hat inzwischen fünf von acht Verdachtsfällen als offizielle Fälle bestätigt. Aus... ► Artikel lesen | |
| NOVAVAX | 8,210 | +0,12 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,790 | +0,72 % | Mesoblast Aktie: Warum sich der Blick auf diesen Biotech-Player jetzt lohnt - und was Anleger von Merck, Regeneron & Co. lernen können | ||
| INOVIO PHARMACEUTICALS | 1,211 | +0,50 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent... ► Artikel lesen | |
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| TREVENA | 4,000 | +1.983 % | TREVENA INC - 8-K, Current Report | ||
| BIOMARIN PHARMACEUTICAL | 45,160 | +0,27 % | BioMarin stock price target raised to $110 by Freedom Broker | ||
| VAXART | 0,380 | 0,00 % | Vaxart anticipates early 2027 primary efficacy readout while aiming for Q2 sentinel data release | ||
| IBIO | 1,437 | +5,12 % | iBio, Inc.: iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors | SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases announced today the appointment... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,670 | -0,54 % | Arbutus Biopharma Corporation: Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B | Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:... ► Artikel lesen | |
| LAKEFRONT BIOTHERAPEUTICS | 23,340 | -0,09 % | Galapagos NV: Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update | Galapagos' name change to Lakefront Biotherapeutics approved at the Company's EGM (Euronext & NASDAQ: LKFT)Collaboration Agreement with Gilead to advance potential First and Best-in-Class T Cell Engager... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,980 | +2,05 % | Cellectar Biosciences, Inc. - 8-K, Current Report | ||
| CYTODYN | 0,282 | 0,00 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer | Program provides access to leronlimab for patients with limited treatment options while supporting ongoing clinical development VANCOUVER, Washington, April 27, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc.... ► Artikel lesen |
Das Unternehmen AROA BIOSURGERY LIMITED kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AROA BIOSURGERY LIMITED finden Sie auf Wallstreet Online.